Verition Fund Management 13F: New $22M Stake in Arcellx (ACLX)
Verition Fund Management opened a new position in Arcellx Inc, picking up 187,354 shares worth roughly $21.6 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Verition Fund Management opened a new position of 187,354 shares in Arcellx Inc ($ACLX), according to a 13F filing with the SEC dated May 15, 2026. It reported 187,354 shares worth $21.56 million at the end of the quarter.
Find the original: Verition Fund Management 13F filings on SEC EDGAR
Key Points
- Verition Fund Management opened a brand-new stake in Arcellx Inc ACLX by purchasing 187,354 shares.
- The newly acquired position had a reported value of about $21.6 million as of the end of the reporting period.
- Arcellx Inc shares recently changed hands near $115.07, close to the company's 52-week high of $115.13.
Get $ACLX trade alerts by text
We text you when insiders, Congress or big funds trade $ACLX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Arcellx Inc alert may contain errors. Disclosures
Verition Fund Management Initiates New Position in Arcellx Inc
Verition Fund Management established a brand-new holding in Arcellx Inc ACLX during the first quarter, according to a Form 13F filed with the U.S. Securities and Exchange Commission. Institutional investment managers submit these quarterly reports to show their equity holdings at the end of each period, though these filings look backward and may not reflect current trading activity.
Breaking Down the New Arcellx Inc Stake
The fund picked up 187,354 shares of the biotechnology company. Based on the filing data, the newly established holding carried an estimated value of $21.6 million. Because this was a new investment for the fund, it represents an entirely fresh addition to their portfolio rather than an adjustment to a previous holding.
Arcellx Inc Shares Trade Near 52-Week Highs
Shares of Arcellx Inc ACLX recently changed hands around $115.07. That price sits just under the company's 52-week high of $115.13 and well above its 52-week low of $50.85. The stock has experienced strong upward momentum, resting comfortably above its 200-day moving average of $84.15 and its 50-day moving average of $112.62.
Inside Arcellx Inc's Pipeline and Operations
Arcellx Inc is a Redwood City, California-based biotechnology firm focused on developing immunotherapies to treat cancer and other serious diseases. Its lead candidate, anitocabtagene autoleucel, is currently being evaluated in a phase 2 clinical trial for patients suffering from relapsed or refractory multiple myeloma. The company operates within the healthcare sector and employs 209 people.
What to Monitor Next
Market participants tracking Verition Fund Management will need to wait for subsequent quarterly disclosures to see if the fund expands or trims its position in Arcellx Inc. Meanwhile, investors will keep an eye on clinical trial updates and upcoming financial reports from the biotechnology firm. These 13F filings offer a snapshot of institutional preferences but do not serve as a recommendation to buy or sell shares.
Related Filing Alerts
Source: Verition Fund Management's 13F filing on $ACLX (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Verition Fund Management 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts